Physician profile
Mark Stavas
NPI 1336468636
$3,531.64
in general payments reported to CMS, 2019-2025
59 companies · $525 in 2025
The $525 reported for 2025 was more than what 75% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $258 · 2021: $302 · 2022: $968 · 2023: $917 · 2024: $306 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $309.17 | 2020-2025 | Keytruda, Lynparza |
| Seagen INC. | $192.48 | 2019-2023 | Adcetris |
| Janssen Biotech, INC. | $192.03 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $183.42 | 2020-2025 | |
| Amgen INC. | $175.54 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Astellas Pharma US INC | $150.55 | 2019-2025 | Vyloy, Padcev |
| Pfizer INC. | $135.53 | 2019-2024 | |
| Daiichi Sankyo INC. | $125.20 | 2020-2024 | Enhertu, Vanflyta |
| Astrazeneca Pharmaceuticals Lp | $122.44 | 2021-2025 | Tagrisso |
| Gilead Sciences, INC. | $119.58 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $105.72 | 2019-2023 | Ninlaro, Iclusig |
| Incyte Corporation | $101.57 | 2020-2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $89.03 | 2019-2023 | Opdivo |
| Siemens Medical Solutions USA, INC. | $86.36 | 2021-2022 | |
| Stemline Therapeutics INC. | $80.72 | 2023-2025 | Orserdu, Elzonris |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stavas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.